Newly emerging therapies targeting viral-related lymphomas

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Gamma-(γ)-herpes virus lymphomas comprise a heterogenous group of B-cell and T-cell neoplasms most commonly associated with Epstein-Barr virus and rarely human herpes virus-8 infection. Adult T-cell leukemia/ lymphoma (ATLL) is a unique disease entity caused by the human T-cell lymphotrophic virus, type 1 (HTLV-I), the only retrovirus known to cause cancer in humans. Viral lymphomas behave aggressively and disproportionally affect immunocompromised individuals and those living in underdeveloped regions. These diseases are often difficult to treat with conventional approaches. Despite recent advancements using cytotoxic, lymphoma-specific, and adoptive therapies, the long-term outcome of patients with γ-herpesvirus lymphomas occurring in severely immunocompromised patients and ATLL continues to be poor. Lytic-inducing therapies targeting NF-κB, and viral and tumor cell epigenetic mechanisms afford the advantage of exploiting the intrinsic presence of oncogenic viruses to eradicate infected tumor cells. In this review, viral-related lymphomas and newly emerging clinical approaches targeting viral latency are discussed.

Original languageEnglish
Pages (from-to)416-426
Number of pages11
JournalCurrent Oncology Reports
Volume13
Issue number5
DOIs
StatePublished - Oct 1 2011

Fingerprint

Lymphoma
Adult T Cell Leukemia Lymphoma
Neoplasms
Virus Latency
Viruses
T-Lymphocytes
Therapeutics
Oncogenic Viruses
Herpesviridae
Immunocompromised Host
Virus Diseases
Retroviridae
Human Herpesvirus 4
Epigenomics
B-Lymphocytes

Keywords

  • Adult T-cell lymphoma
  • Adult Tcell leukemia
  • AIDS-related lymphomas
  • EBV
  • Epstein-Barr virus
  • Gamma herpesvirus
  • HDAC inhibitors
  • HHV-8
  • HIV
  • HTLV-I
  • Human herpes virus-8
  • Human immunodeficiency virus
  • Human T-cell lymphotrophic virus
  • KSHV
  • Lymphoma
  • Lytic therapies
  • NF-κB
  • Nuclear factor kappa B
  • Oncology
  • Plasmablastic lymphoma
  • Primary effusion lymphoma
  • Type 1 human T-cell leukemia virus
  • Viral latency
  • Viral lymphomas

ASJC Scopus subject areas

  • Oncology

Cite this

Newly emerging therapies targeting viral-related lymphomas. / Carlos Ramos, Juan; Lossos, Izidore.

In: Current Oncology Reports, Vol. 13, No. 5, 01.10.2011, p. 416-426.

Research output: Contribution to journalArticle

@article{2fffc0b10f5240fe81a9fc6faf617c84,
title = "Newly emerging therapies targeting viral-related lymphomas",
abstract = "Gamma-(γ)-herpes virus lymphomas comprise a heterogenous group of B-cell and T-cell neoplasms most commonly associated with Epstein-Barr virus and rarely human herpes virus-8 infection. Adult T-cell leukemia/ lymphoma (ATLL) is a unique disease entity caused by the human T-cell lymphotrophic virus, type 1 (HTLV-I), the only retrovirus known to cause cancer in humans. Viral lymphomas behave aggressively and disproportionally affect immunocompromised individuals and those living in underdeveloped regions. These diseases are often difficult to treat with conventional approaches. Despite recent advancements using cytotoxic, lymphoma-specific, and adoptive therapies, the long-term outcome of patients with γ-herpesvirus lymphomas occurring in severely immunocompromised patients and ATLL continues to be poor. Lytic-inducing therapies targeting NF-κB, and viral and tumor cell epigenetic mechanisms afford the advantage of exploiting the intrinsic presence of oncogenic viruses to eradicate infected tumor cells. In this review, viral-related lymphomas and newly emerging clinical approaches targeting viral latency are discussed.",
keywords = "Adult T-cell lymphoma, Adult Tcell leukemia, AIDS-related lymphomas, EBV, Epstein-Barr virus, Gamma herpesvirus, HDAC inhibitors, HHV-8, HIV, HTLV-I, Human herpes virus-8, Human immunodeficiency virus, Human T-cell lymphotrophic virus, KSHV, Lymphoma, Lytic therapies, NF-κB, Nuclear factor kappa B, Oncology, Plasmablastic lymphoma, Primary effusion lymphoma, Type 1 human T-cell leukemia virus, Viral latency, Viral lymphomas",
author = "{Carlos Ramos}, Juan and Izidore Lossos",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s11912-011-0186-8",
language = "English",
volume = "13",
pages = "416--426",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Newly emerging therapies targeting viral-related lymphomas

AU - Carlos Ramos, Juan

AU - Lossos, Izidore

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Gamma-(γ)-herpes virus lymphomas comprise a heterogenous group of B-cell and T-cell neoplasms most commonly associated with Epstein-Barr virus and rarely human herpes virus-8 infection. Adult T-cell leukemia/ lymphoma (ATLL) is a unique disease entity caused by the human T-cell lymphotrophic virus, type 1 (HTLV-I), the only retrovirus known to cause cancer in humans. Viral lymphomas behave aggressively and disproportionally affect immunocompromised individuals and those living in underdeveloped regions. These diseases are often difficult to treat with conventional approaches. Despite recent advancements using cytotoxic, lymphoma-specific, and adoptive therapies, the long-term outcome of patients with γ-herpesvirus lymphomas occurring in severely immunocompromised patients and ATLL continues to be poor. Lytic-inducing therapies targeting NF-κB, and viral and tumor cell epigenetic mechanisms afford the advantage of exploiting the intrinsic presence of oncogenic viruses to eradicate infected tumor cells. In this review, viral-related lymphomas and newly emerging clinical approaches targeting viral latency are discussed.

AB - Gamma-(γ)-herpes virus lymphomas comprise a heterogenous group of B-cell and T-cell neoplasms most commonly associated with Epstein-Barr virus and rarely human herpes virus-8 infection. Adult T-cell leukemia/ lymphoma (ATLL) is a unique disease entity caused by the human T-cell lymphotrophic virus, type 1 (HTLV-I), the only retrovirus known to cause cancer in humans. Viral lymphomas behave aggressively and disproportionally affect immunocompromised individuals and those living in underdeveloped regions. These diseases are often difficult to treat with conventional approaches. Despite recent advancements using cytotoxic, lymphoma-specific, and adoptive therapies, the long-term outcome of patients with γ-herpesvirus lymphomas occurring in severely immunocompromised patients and ATLL continues to be poor. Lytic-inducing therapies targeting NF-κB, and viral and tumor cell epigenetic mechanisms afford the advantage of exploiting the intrinsic presence of oncogenic viruses to eradicate infected tumor cells. In this review, viral-related lymphomas and newly emerging clinical approaches targeting viral latency are discussed.

KW - Adult T-cell lymphoma

KW - Adult Tcell leukemia

KW - AIDS-related lymphomas

KW - EBV

KW - Epstein-Barr virus

KW - Gamma herpesvirus

KW - HDAC inhibitors

KW - HHV-8

KW - HIV

KW - HTLV-I

KW - Human herpes virus-8

KW - Human immunodeficiency virus

KW - Human T-cell lymphotrophic virus

KW - KSHV

KW - Lymphoma

KW - Lytic therapies

KW - NF-κB

KW - Nuclear factor kappa B

KW - Oncology

KW - Plasmablastic lymphoma

KW - Primary effusion lymphoma

KW - Type 1 human T-cell leukemia virus

KW - Viral latency

KW - Viral lymphomas

UR - http://www.scopus.com/inward/record.url?scp=80755133369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755133369&partnerID=8YFLogxK

U2 - 10.1007/s11912-011-0186-8

DO - 10.1007/s11912-011-0186-8

M3 - Article

VL - 13

SP - 416

EP - 426

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

ER -